Tag: podcast

Categories : Ageing Obstetrics & GynaecologyTags : Leave a comment

Study Finds ‘Physiological Cliff’ Hidden in Menopause Data

On By ModernMedia
Image generated with AI

Studies on menopause have always had to cope with the date of the final menstrual period varying enormously, which blurred the data due to the variable onset ages. But a innovative technique finds a distinct ‘physiological cliff’ related to the onset of menopause – and significant changes for a decade and a half preceding it.

To get around the problem of the variable onset age of menopause, researchers made use of a computational method originally used for astronomy and applied it to map large-scale biomedical datasets by anchoring health markers to the final menstrual period.

By analysing hundreds of millions of laboratory tests from two independent populations, scientists uncovered a step-like physiological cliff across endocrine, skeletal, hepatic, renal, and lipid systems that coincides precisely with menopause. These abrupt physiological shifts – which are of course completely absent in male control cohorts – often signal an increased risk of disease and begin more than a decade before menstruation permanently ceases. Furthermore, the analysis demonstrates that menopausal hormone therapy significantly attenuates these abrupt biological disruptions, restoring postmenopausal test trajectories to resemble a smoother continuation of earlier health patterns.

Listen to our podcast for more details!

Categories : Immunology Mental HealthTags :

Autoantibodies and Blood–Brain Barrier Dysfunction in Schizophrenia

On By ModernMedia
Source: CC0

A growing body of research has shown that autoimmunity influences certain psychiatric disorders. A new study by Nemani et al., currently in preprint, has shown that schizophrenia is strongly associated with an elevated level of autoantibodies that target the central nervous system. Using Rapid Extracellular Antigen Profiling (REAP) to screen 352 patients against 971 controls, the researchers found that schizophrenia is marked by an increased autoantibody burden that tracks with disease severity and duration, nearly doubling in the most chronic cases.

These immune responses are present near the start of the illness and tend to increase as the disease progresses, particularly targeting neuronal ion channels and synaptic proteins. Notably, certain autoantibodies appear to compromise the blood–brain barrier, which may further expose the brain to peripheral immune attacks.

The study also discovered that patients with a higher autoantibody burden respond less effectively to standard antipsychotic treatments like risperidone. However, clinical trials showed that these antibody levels significantly declined during successful treatment courses. These findings suggest that humoral autoimmunity is a core component of the disorder, potentially offering new pathways for immune-based therapies.

The article is available on the BioRxiv preprint server.

Listen to our podcast below!

Categories : Cardiovascular DiseaseTags :

Certain Combinations of Antihypertensives Are More Tolerable, Study Finds

On By ModernMedia
Credit: Pixabay CC0

Getting patients to adhere to antihypertensive drugs is a major obstacle in controlling hypertension and cardiovascular risk. To find out which drugs or combinations of drugs have the best adherence rates, researchers conducted a comprehensive network meta-analysis of the five primary classes of blood pressure-lowering medications. The research, published in JAMA Network, examined short-term tolerability and side-effect profiles in data from over 700 clinical trials, and identifies significant variations in treatment discontinuation rates across different drug categories and combinations.

The most well-tolerated options were angiotensin II receptor blockers (ARBs), both alone and paired with calcium channel blockers – often showing fewer withdrawals than placebos. While most therapies successfully reduced headaches, they simultaneously increased instances of dizziness and hypotension-related symptoms. These findings suggest that specific combination therapies may offer better patient outcomes and superior symptomatic improvement compared to traditional single-drug treatments. Ultimately, the study provides a robust framework for clinicians to better manage patient-reported adverse events during the initial months of hypertension care.

Categories : Metabolic Disorders Respiratory DiseasesTags :

Could an Asthma Medication Also Protect Against MASH?

On By ModernMedia
Credit: Pixabay CC0

Join our podcast as we unpack a study exploring the potential of the asthma medication formoterol as a novel treatment for Metabolic Dysfunction-Associated Steatohepatitis (MASH), a severe liver condition often linked to diabetes.

The researchers used experiments involving high-fat diet mice and human liver cell cultures to show that this beta 2 adrenergic receptor agonist effectively reduces liver fat accumulation. It does so by stimulating mitochondrial biogenesis and enhancing metabolic efficiency. In addition, a massive retrospective analysis of nearly 60 000 patients revealed that those using long-acting versions of these drugs experienced significantly lower rates of liver complications and reduced mortality.

Categories : Cardiovascular DiseaseTags :

Lipid Lowering: Why 70mg/dL May Not Be Low Enough

On By ModernMedia
Image by Scientific Animations, CC4.0

Current clinical guidelines stress that lower LDL cholesterol levels significantly reduce the risk of major cardiac events. Essential strategies for treatment include heart-healthy lifestyle changes and pharmacological interventions using statins, ezetimibe, and PCSK9 inhibitors. Early intervention is vital, as the cumulative exposure to high cholesterol over time – often termed “LDL years” – determines the onset of vascular disease. But a major question has remained as to whether more aggressive lip-lowering targets is worth the potential side effects such as kidney damage.

Now, a new clinical trial published in NEJM provides evidence that an intensive target of less than 55mg/dL is superior for preventing secondary complications. In the Ez-PAVE trial, researchers in South Korea investigated whether this more intensive provided better protection than the conventional goal of less than 70mg/dL. The study found that patients in the intensive group experienced a significant reduction in cardiovascular events over a three-year period. The researchers conclude that their findings support stricter lipid-lowering guidelines, which can safely and effectively improve long-term patient outcomes.

Categories : Metabolic Disorders RheumatologyTags :

Can GLP-1 Agonists ‘Change the Weather’ for Osteoarthritis?

On By ModernMedia
Photo by Towfiqu barbhuiya

For GPs, solutions for treating osteoarthritis are frustratingly limited – it’s like the weather, everyone talks about it but nobody does anything about it. While standard care can relieve symptoms, there is currently no way to regenerate the actual lost cartilage in the joints. Some experimental treatments have proven successful in animal models and in petri dishes, but those are still many years away from being approved and available on the market.

But what if there was a currently available drug that could be repurposed? Since overweight and obesity worsen osteoarthritis symptoms by placing excess strain on weight-bearing joints, GLP-1 agonists such as semaglutide have proven that they can help by promoting rapid weight loss, as demonstrated by the STEP-9 trial.

Research into GLP-1s has now revealed that they may offer a whole constellation of other benefits, such as a potential reduction in stroke risk. Now, it appears that GLP-1 agonists may have a direct effect on osteoarthritis independent of weight loss. In our podcast, we look at a recently published article in Cell Metabolism that suggests that GLP-1 agonists might go beyond just the weight loss – promote actual cartilage regrowth by jumpstarting the joint cells’ energy processing pathways. We also explore some of the caveats of potentially using GLP-1 agonists in this way, such as a lack of understanding of the long term effects, as well as the well-documented occurrence of muscle loss.

Categories : Metabolic DisordersTags :

Oral PCSK9 Inhibitor Offers Cholesterol Control Without the Needle

On By ModernMedia
Photo by Danilo Alvesd on Unsplash

The results of a phase 3 clinical trial for enlicitide, a novel oral medication designed to lower cholesterol have been reported in a recent New England Journal of Medicine article. The study, involving nearly 3000 adults with existing or at high risk of cardiovascular disease, compared a daily 20mg dose against a placebo over one year.

Researchers found that the drug significantly reduced LDL cholesterol by approximately 57% within 24 weeks, alongside notable decreases in other harmful lipids. These improvements remained consistent and durable throughout the 52-week treatment period. Crucially, the safety profile of the oral inhibitor appeared comparable to the placebo, with no meaningful difference in side effects. The authors conclude that this convenient pill could offer a highly effective alternative to existing injectable therapies for managing heart disease risk.

Listen to a discussion on QuickNews’ podcast!

Categories : Cardiovascular Disease Diet and NutritionTags :

Is Caffeine Actually Getting an Unfair Rap in Atrial Fibrillation?

On By ModernMedia
Photo by Porapak Apichodilok on Pexels

Caffeine may have been unfairly portrayed as the villain in some heart rhythm disorders, according to a new study published in the Journal of the American Medical Association.

Longstanding medical advice has held that patients with atrial fibrillation (AF) should cut back on their caffeine intake – or eliminate it entirely – to improve their condition. Wong et al. conducted an investigation into the relationship between regular caffeinated coffee consumption and the recurrence of atrial fibrillation (AF) or atrial flutter.

The DECAF randomised clinical trial, conducted across five international centres, enrolled 200 patients with persistent AF who were successfully cardioverted and then randomised to either consume caffeinated coffee (averaging one cup daily) or abstain from coffee and caffeine for six months. But contrary to expectations, the caffeine group actually saw an improvement in symptoms.

Listen to the podcast:

Categories : NeurologyTags :

Could a New Way to Restore Lithium Deficiency in Alzheimer’s Really Work?

On By ModernMedia
Neurons in the brain of an Alzheimer’s patient, with plaques caused by tau proteins. Credit: NIH

It has been known that brain lithium (Li) levels are depleted in individuals with mild cognitive impairment, a precursor for Alzheimer’s disease. For years, there have been attempts to restore Li levels to prevent Alzheimer’s disease by administering lithium carbonate. But now, it has been shown that the Li from this compound has been sequestered and not actually restoring the endogenous Li levels. Now, scientists have tried using lithium oxide (LiO) salts instead – and the treatment appears to be effective in prevention and even reversal of a mouse model of Alzheimer’s.

Join our QuickNews podcast as the arguments for and against this lithium-based approach are unpacked and debated.

Categories : Metabolic DisordersTags :

Unmasking a New Diabetes Subtype in Sub-Saharan Africa

On By ModernMedia
Photo by Wes Dissy on Unsplash

In this month’s podcast, QuickNews looks at a new Lancet study, “Non-autoimmune, insulin-deficient diabetes in children and young adults in Africa.” In this study, researchers report that a significant subset of what has previously been classified as Type 1 diabetes in sub-Saharan Africa may in fact be a distinct, novel form of the disease.

The individuals in this subset did not exhibit the typical autoimmune markers (islet autoantibodies) usually found in classic Type 1 diabetes in other parts of the world. The researchers instead identified a novel, non-autoimmune, insulin-deficient subtype of diabetes that is also distinct from Type 2 diabetes.

Further evidence of this new subtype was found in Black individuals in the USA, albeit less frequently, but not in White individuals. The discovery throws a spotlight on the heterogeneity of diabetes diagnoses in sub-Saharan Africa, and points to the need to consider alternative causes and explore new prevention and treatment strategies for this distinct form of the disease.